Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00371397 · ClinicalTrials.gov registry record · NA
Yoga, Immune Function, and Health
A NA study, sponsored by Ohio State University.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
NCT00371397: Completed NA study, sponsored by Ohio State University.
NCT00371397 is a NA study that has completed, run by Ohio State University. The registered enrollment target is 52 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00371397, a NA study, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
Study Summary
This study is designed to examine the impact of hatha yoga on immune and hormonal functioning in healthy individuals.
Primary Outcome
High sensitivity C-reactive protein (hsCRP) assessed once at baseline, at each of the three visits. The hsCRP assay was performed using chemiluminescence methodology with the Immulite 1000 (Siemens Medical Solutions, Los Angeles, Ca.) The lowest level of detection is .3 mg/dL. 43% of the values were below this lower bound, thus hsCRP was dichotomized as undetectable/detectable.
Interventions
- BEHAVIORAL Hatha Yoga Classes
- BEHAVIORAL Movement Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2005-09 |
| Est. Completion | 2008-09 |
| Phase | NA |
What the finished NCT00371397 record still lists
NCT00371397 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Hatha Yoga Classes is the first listed.
NCT00371397 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00371397 about?
NCT00371397 is a clinical study titled "Yoga, Immune Function, and Health". This study is designed to examine the impact of hatha yoga on immune and hormonal functioning in healthy individuals.
What is the current status of trial NCT00371397?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2005-09. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00371397?
The interventions under investigation include: Hatha Yoga Classes (BEHAVIORAL), Movement Control (BEHAVIORAL).
Who is sponsoring clinical trial NCT00371397?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00371397's enrollment target sits among peer trials
52 1272nd of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia